Abstract:
Objective To evaluate the efficacy and the safety of nab-paclitaxel in advanced solid tumor patients.
Methods Twenty-five patients with solid tumor received nab-paclitaxel-based (nab-paclitaxel 130 mg/m2dl, 8) regimes every 3 wk. All of the patients were evaluated for efficacy and safety at least after 2 cycles.
Results Of the 25 patients, 14 had partial response whereas 5 had stable disease. The response and clinical benefit rates were 59% and 76%, respectively. The median time to progression was 5.6 months. The predominant toxicities were neutropaenia (12%), neuropathy (8%), and muscle pain (12%).
Conclusion The nab-paclitaxel-based regimen was effective and tolerable in advanced solid tumor.